Panel on Investment Opportunities with VCs at CNS Partnering meeting Sept 13-14, San Francisco

MONROVIA, CA, July 28, 2012 (Press-News.org) Novo Ventures, Third Rock Ventures, Abingworth Management and TPG Biotech will speak in a Panel Discussion on "Investment Opportunities with Venture Capital" at the 5th CNS Partnering and Deal-making Conference to be held in San Francisco, CA on September 13-14, 2012.

Representatives from leading venture capital companies are:
Heath Lukatch, Ph.D., Partner, Novo Ventures
Kiran Reddy, M.D., Principal, Third Rock Ventures
Ken Haas, Venture Partner, Abingworth Management
Eran Nadav, Ph.D MBA, Managing Director, TPG Biotech

The panel discussion will focus on the following topics:
• What is the best way to work with venture capitalists (e.g., typical deal structures, management)? There is real benefit in forming collaborations between venture backed companies and non-industry supporters like philanthropy money, patient advocate groups, and even crowd funding. This type of collaboration can facilitate drug development and make more products available for patients.
• Major neurological disorders (Parkinson's AD, stroke...) vs. orphan/niche/white-space neurological indication. What are the investment considerations and prospects?
• New science and new modalities in treating neurological disorders: glia cells, deep brain stimulation, brain-machine interface, gene therapy... - Are these novel approaches mature enough to be fundable?
• What neurology investments VCs are looking for in the current environment?
• The search after disease modifying therapies in neurology
• What kinds of CNS opportunities / sub-indications are most suitable to venture capital?
• What are the challenges in CNS for venture capital firms (e.g., relative to other fields)?
• When is a company or project ready to raise venture capital?
• What is the best way to approach venture capital firms?

The 5th CNS Partnering and Deal-making is a CNS Diseases partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant CNS Disease issues and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about CNS Diseases business development trends, the CNS disease market, and novel technologies that shape up the industry.

The conference is part of the CNS Diseases World Summit, which consists of 4 parallel tracks:
1) 6th Neurodegenerative Conditions Research and Development
2) 5th CNS Partnering and Deal-making
3) 2nd Neuropsychiatric Research and Development
4) Pain Research and Therapeutics

For more information, please visit http://www.gtcbio.com

ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com